Article

Study Finds Cancer Care Patterns May Not be Influenced by Fee-for-Service Reimbursement

Research suggests salaried physicians practice in the same manner as those reimbursed by fee-for-service methodology.

Research suggests salaried physicians practice in the same manner as those reimbursed by fee-for-service methodology.

A recent study finds that a novel reimbursement model does not alter physician prescribing behavior regarding the type or frequency of chemotherapy administrations, or new patient visits. The study, published online April 21, 2014 on AJMC.com, states that the influence of a fee-for-service reimbursement model is not as prevalent in oncology treatment selection and cancer care practice patterns as it is commonly believed to be.

The researchers state that hospice referral rates, hospitalizations, intensive care admissions, and the use of chemotherapy during the final weeks of life are similar between salaried physicians and those reimbursed by fee-for-service methodology, regardless of varying financial incentives.

Click here to visit AJMC.com for the full study.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards